Peptide-chaperone-directed transdermal protein delivery requires energy

Mol Pharm. 2014 Nov 3;11(11):4015-22. doi: 10.1021/mp500277g. Epub 2014 Oct 13.

Abstract

The biologically inspired transdermal enhanced peptide TD1 has been discovered to specifically facilitate transdermal delivery of biological macromolecules. However, the biological behavior of TD1 has not been fully defined. In this study, we find that energy is required for the TD1-mediated transdermal protein delivery through rat and human skins. Our results show that the permeation activity of TD1-hEGF, a fusion protein composed of human epidermal growth factor (hEGF) and the TD1 sequence connected with a glycine-serine linker (GGGGS), can be inhibited by the energy inhibitor, rotenone or oligomycin. In addition, adenosine triphosphate (ATP), the essential energetic molecule in organic systems, can effectively facilitate the TD1 directed permeation of the protein-based drug into the skin in a dose-dependent fashion. Our results here demonstrate a novel energy-dependent permeation process during the TD1-mediated transdermal protein delivery that could be valuable for the future development of promising new transdermal drugs.

Keywords: ATP; energy; peptide chaperon; transdermal drug delivery; transdermal peptide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Animals
  • Drug Delivery Systems*
  • Energy Metabolism / drug effects*
  • Epidermal Growth Factor / administration & dosage*
  • Humans
  • Molecular Chaperones*
  • Oligomycins / pharmacology
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Rotenone / pharmacology
  • Skin / drug effects
  • Skin / metabolism*
  • Skin / pathology
  • Skin Absorption / drug effects
  • Uncoupling Agents / pharmacology

Substances

  • Molecular Chaperones
  • Oligomycins
  • Peptide Fragments
  • Uncoupling Agents
  • Rotenone
  • Epidermal Growth Factor